Logo image
Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma
Journal article   Open access   Peer reviewed

Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma

Mary Ann Comunale, Mengjun Wang, Lucy Rodemich-Betesh, Julie Hafner, Anne Lamontagne, Andrew Klein, Jorge Marrero, Adrian M Di Bisceglie, Robert Gish, Timothy Block, …
Cancer epidemiology, biomarkers & prevention, v 20(6), pp 1222-1229
Jun 2011
PMID: 21467232
url
https://doi.org/10.1158/1055-9965.EPI-10-1047View
Published, Version of Record (VoR) Open

Abstract

Liver Cirrhosis - diagnosis Carcinoma, Hepatocellular - diagnosis Humans Middle Aged Risk Factors Electrophoresis, Gel, Two-Dimensional Male Clusterin - blood Glycosylation Liver Cirrhosis - blood Case-Control Studies Polysaccharides - analysis Biomarkers, Tumor - blood Liver Neoplasms - blood Tandem Mass Spectrometry Liver Neoplasms - diagnosis Chromatography, Liquid Female ROC Curve Carcinoma, Hepatocellular - blood Neoplasm Staging alpha-Fetoproteins - metabolism
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and the occurrence of HCC has more than doubled in the United States in the past decade. Early detection is considered key to reducing the mortality of HCC. Using two-dimensional gel electrophoresis and high-performance liquid chromatography we have analyzed the glycosylation of Apo-J from healthy controls, patients with liver cirrhosis, or those with HCC. Apo-J in the serum from patients with HCC had decreased levels of (β-1,4) triantennary N-linked glycan compared with the healthy controls or patients with liver cirrhosis. We analyzed this change in an independent cohort of 76 patients with HCC, 32 with cirrhosis, and 43 infected with hepatitis C virus using the Datura stramonium lectin (DSL), which binds to (β-1,4) triantennary N-linked glycan. The level of DSL-reactive Apo-J allowed us to differentiate HCC from cirrhosis with an area under the receiver operating characteristic curve (AUROC) of 0.852. When Apo-J was combined with other serum biomarkers such as α-fetoprotein (AFP) and fucosylated kininogen by using a multivariate logistic regression model, the AUROC increased to 0.944, a value much greater than that observed with AFP alone (AUROC of 0.765). The glycosylation of Apo-J is a useful marker when used alone or in combination with outer makers for the early detection of HCC. The potential use of a combination of AFP, DSL-reactive Apo-J, and fucosylated kininogen as a biomarker of HCC would have great value in the management of patients with liver disease.

Metrics

10 Record Views
40 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Public, Environmental & Occupational Health
Logo image